Caroline Palomeque
Stock Analyst at Maxim Group
(1.30)
# 3,588
Out of 4,974 analysts
10
Total ratings
44.44%
Success rate
-0.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $2.15 | +272.09% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $35.99 | +63.93% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $150.27 | +2.48% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $74.93 | -22.59% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $206.03 | -19.43% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $15.43 | +152.75% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.71 | +528.22% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $9.39 | +325.99% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $2.15
Upside: +272.09%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $35.99
Upside: +63.93%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $150.27
Upside: +2.48%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $74.93
Upside: -22.59%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $206.03
Upside: -19.43%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $15.43
Upside: +152.75%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.71
Upside: +528.22%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $9.39
Upside: +325.99%